(MedPage Today) -- The RED-HF trial, testing darbepoetin alfa (Aranesp) in heart failure patients with anemia, failed to meet its primary endpoint, according to top-line results released by Amgen. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment